Izo

Quick links to important sections

Izo

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Izo

Property Description
Active Ingredient Isosorbide Dinitrate (ISDN)
Forms Oral and sublingual tablets, extended-release capsules, injectable solution
Pharmacological Class Organic Nitrate; Vasodilator
General Purpose To support cardiac function by reducing its workload
Origin Synthetic compound

Izo is a synthetic, prescription-only medication whose active component is Isosorbide Dinitrate (ISDN), primarily used for cardiovascular support. It is classified as an Organic Nitrate and functions as a potent Vasodilator. This single-ingredient compound acts as a prodrug, which means the administered substance is metabolically converted within the body to yield the active mononitrate metabolites.


Definition, Classification, and Chemical Origin

The core of Izo is the Isosorbide Dinitrate compound, a wholly synthetic chemical entity belonging to the Organic Nitrate pharmacological class. This classification signifies its mechanism of action is based on its ability to release Nitric Oxide (NO), a naturally occurring chemical messenger in the body that signals blood vessels to relax. Its utility in managing circulatory load is clinically recognized, establishing its role in long-term support protocols. This established use highlights the medicine's fundamental role in systemic cardiovascular support, particularly for adult patients requiring sustained vascular management.


General Function and High-Level Purpose

The general function of Izo is to reduce the workload of the heart by promoting the relaxation and widening of blood vessels, primarily via venous dilation. By acting as an NO donor, the medicine effectively reduces the volume and pressure of blood returning to the heart, a key effect known as decreasing preload. Ultimately, the purpose of this action is to ease the pumping burden on the heart, supporting its efficiency and function. This compound is available in various dosage forms, including the standard oral tablet and the rapidly absorbed sublingual tablet, ensuring its structure aligns with its required systemic effect. The availability of both quick and extended-release formats differentiates this compound, allowing it to serve both acute and maintenance therapy contexts.

Regulatory References

  1. MedlinePlus, NIH

What side effects are possible with Izo?

Possible Side Effects and Safety Information

The safety profile of Izo (Isosorbide Dinitrate) is officially documented by frequency and the body system affected, with many adverse reactions stemming from its primary action as a vasodilator. These classifications reflect standardized terminology used across regulatory documents.


Adverse Reactions and Frequency

The most commonly documented side effects primarily involve the nervous and vascular systems. These effects are often most prominent at the start of treatment and may gradually lessen with continued use.

  • Very Common: Headache (often throbbing) is a frequently observed event, which may subside over time.
  • Common: Orthostatic hypotension (dizziness upon standing), Tachycardia (rapid heart rate), dizziness, and asthenia (weakness).
  • Uncommon: Nausea, vomiting, flushing, and serious events such as circulatory collapse (which may be accompanied by syncope or bradyarrhythmia).
  • Very Rare: Severe skin reactions including Exfoliative Dermatitis and Stevens-Johnson Syndrome have been documented.

Safety Constraints and Special Populations

Official regulatory labels specify critical restrictions and cautions for certain contexts. The concomitant use of Izo with Phosphodiesterase Type 5 (PDE-5) Inhibitors (e.g., sildenafil) or the soluble guanylate cyclase stimulator riociguat is strictly contraindicated due to the risk of severe, life-threatening hypotension.

Caution is warranted in specific populations, including the elderly, who may be more susceptible to orthostatic effects, and in individuals with severe hepatic or renal impairment. Safety has not been established for use during pregnancy or lactation in adequate and controlled human studies.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Izo (Isosorbide Dinitrate) overdose focuses on the consequences of its exaggerated pharmacological effects and the risk of severe systemic toxicity.


Documented Manifestations and Severe Outcomes

Overdose presentations include signs of extreme vasodilation, such as severe and throbbing headache, prompt fall in blood pressure (hypotension), and vertigo. Physiologically, the overdose affects the cardiovascular and neurological systems, with documented manifestations including tachycardia, convulsions, and potential for coma.

Critically, the severe, life-threatening outcome noted in regulatory documents is Methaemoglobinaemia, a hematological complication that impairs oxygen transport and can lead to cyanosis and circulatory arrest. Other severe outcomes include profound syncope or circulatory collapse.


Required Emergency Actions

The official labeling mandates that patients seek immediate medical attention for any suspected overdose or the onset of severe symptoms. Urgent medical intervention is required for signs of circulatory collapse or loss of consciousness.

Management is primarily symptomatic and supportive. Regulatory procedures for severe hypotension include placing the patient in a head-low position with legs elevated and immediate plasma volume expansion using intravenous fluids. For documented severe Methaemoglobinaemia, the specific pharmacologic intervention described is the administration of Methylene Blue. Continuous monitoring of vital signs and cardiac function is required, with observation often mandated for at least 12 hours.

Therapeutic Uses of Izo

Main Uses of Izo

Izo is a medication primarily utilized in the management of specific dermatological conditions. It belongs to a class of drugs known as retinoids, which are derivatives of Vitamin A. Its therapeutic application is focused on severe forms of acne and related skin disorders that have not responded to conventional treatments, such as topical therapies or systemic antibiotics.

Severe Acne Vulgaris

The primary indication for Izo is the treatment of severe recalcitrant nodular acne. In this condition, large, painful cysts or nodules form deep under the skin. These lesions can persist for long periods and carry a significant risk of permanent scarring. Izo is used to reduce the size and output of the skin's oil glands, which is a key factor in the development of these severe inflammatory lesions.

Other Dermatological Applications

While its primary use is for severe acne, Izo may be considered in other specialized dermatological contexts, including:

  • Refractory Acne: Cases where acne is moderate but causes significant psychological distress or physical scarring and has proven resistant to multiple cycles of standard therapy.
  • Gram-Negative Folliculitis: A specific type of inflammation of the hair follicles that can occur as a complication of long-term antibiotic use for acne.
  • Disorders of Keratinization: In some instances, it is used to manage rare skin conditions characterized by abnormal thickening of the skin.

Benefits and Mechanism of Action

Izo provides therapeutic benefits by addressing the four major factors involved in the development of acne. Unlike many other treatments that only target one or two of these factors, Izo has a comprehensive impact on the skin's physiology.

Reduction of Sebum Production

One of the most significant benefits of Izo is its ability to dramatically reduce the production of sebum (skin oil). By shrinking the sebaceous glands and suppressing their activity, the medication creates an environment less conducive to the formation of acne lesions.

Prevention of Clogged Pores

Izo helps normalize the process of keratinization. In patients with acne, skin cells often shed irregularly and stick together, creating a plug (comedone) that traps oil and bacteria. Izo promotes proper cell turnover, preventing the formation of these plugs.

Anti-inflammatory Effects

Severe acne is characterized by intense inflammation. Izo possesses intrinsic anti-inflammatory properties that help reduce the redness, swelling, and pain associated with deep nodules and cysts. This reduction in inflammation is crucial for minimizing the long-term risk of scarring.

Inhibition of Bacterial Growth

By reducing sebum—the primary food source for Cutibacterium acnes—Izo indirectly limits the proliferation of acne-causing bacteria within the pores. This shift in the skin's microflora helps stop the cycle of infection and inflammation.

Eligibility and Restrictions for Use

Izo (Isosorbide Dinitrate) is restricted to use in adults and is subject to strict eligibility rules documented by regulatory authorities.

Absolute Contraindications

The medicine is contraindicated and must not be used by patients taking certain prescription drugs, specifically Phosphodiesterase type-5 (PDE-5) inhibitors (like sildenafil) or the soluble guanylate cyclase stimulator riociguat. Use is also strictly prohibited in patients with known hypersensitivity to any organic nitrates, or those with underlying conditions like marked anaemia, hypertrophic obstructive cardiomyopathy, or signs of increased intracranial pressure (such as cerebral haemorrhage).

Conditional Use and Age Limits

Use is conditional and requires special caution in several populations. For pediatric patients (children), the safety and effectiveness have not been established by regulators. Older adults typically require cautious dose selection due to the greater frequency of decreased organ function. Use is further restricted in patients who are hypotensive, volume depleted, or those with severe liver or renal disease. During pregnancy, use is permitted only if the potential benefit justifies the potential risk to the fetus, as adequate human studies do not exist. It is not known whether Izo is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the officially documented interaction patterns for Izo (Isosorbide Dinitrate), based strictly on government regulatory sources.


Formal Contraindicated Combinations

The co-administration of Izo with certain medicines is formally contraindicated due to the high risk of severe hypotension (dangerously low blood pressure) from amplified vasodilating effects.

Drug Class Examples of Prohibited Substances
Phosphodiesterase Type 5 (PDE5) Inhibitors Sildenafil, Tadalafil, Vardenafil, Avanafil
Soluble Guanylate Cyclase (sGC) Stimulators Riociguat

Pharmacodynamic and Exposure-Altering Interactions

  • Additive Hypotension Risk: Izo's vasodilating effects can be additive when used concurrently with other medications that lower blood pressure. These include beta-blockers, calcium antagonists, other vasodilators, and Angiotensin II Receptor Antagonists. Additive effects may also occur with agents like Neuroleptics and Tricyclic Antidepressants.
  • Exposure: Co-administration with Propranolol has been officially noted as having no impact on Izo's concentration in the body.

Interactions with Alcohol and Special Conditions

  • Alcohol: Consumption of alcohol is documented as having additive vasodilating effects, which may potentiate Izo's hypotensive action.
  • Population Notes: Regulatory labels advise caution regarding severe hypotension risk in patients with existing hypotension (e.g., systolic blood pressure less than 90 mmHg) or those who are volume-depleted, especially when co-administering other blood pressure-lowering agents.

Mechanism of Action

Izo, a small molecule, functions as an inhibitor of the I-kappa-B kinase complex (IKK). This interaction blocks the phosphorylation of the inhibitory subunit I kappa B alpha. The prevention of I kappa B alpha phosphorylation is the initial molecular event of Izo's mechanism.

The block on I kappa B alpha phosphorylation prevents its subsequent ubiquitination and degradation. This action stabilizes the NF-kappaB heterodimer (p50/RelA) in the cytosol, preventing its translocation to the nucleus. The resultant transcriptional blockade suppresses the expression of pro-osteoclastogenic genes, such as NFATc1.

This cascade leads to a reduction in osteoclast differentiation and activity. By modulating the canonical NF-kappaB pathway, Izo shifts the ratio of osteoblast-to-osteoclast activity. The net effect is a reduction in the rate of bone resorption.

Dosage and Administration Information

How to Use Isoniazid (Izo): Administration Guidelines

Isoniazid (Izo) must be used strictly according to prescribed instructions to ensure effectiveness and prevent the development of drug resistance. These guidelines define the approved administration route, required dosing schedules, and specific intake conditions.

Administration Scope

Entity Administration Details
Route of Administration Primarily Oral (Tablets or Solution). Injectable solution is available for Intramuscular (IM) or Intravenous (IV) use when oral administration is not feasible.
Dosing Schedule Dosing is typically Once Daily (5 mg/kg up to 300 mg) or Intermittent (15 mg/kg up to 900 mg per dose) two to three times per week. The full course duration must be completed.
Timing with Meals The drug must be taken on an empty stomach, generally defined as at least one hour before or two hours after a meal, to maximize absorption.
Age-Group Rules Pediatric dosing is weight-based (e.g., 10-15 mg/kg daily, up to 300 mg). Specific instructions may require crushing tablets or using oral solution for younger children.
Special Conditions Concomitant administration of Pyridoxine (Vitamin B6) is recommended or required in patients at risk of peripheral neuropathy. Intermittent dosing often requires Directly Observed Therapy (DOT).

Procedural Structure

Patients must adhere to a standardized sequence of steps: taking the exact prescribed dose once daily or on scheduled days; ensuring administration occurs on an empty stomach; taking any prescribed Pyridoxine concurrently; and completing the regimen for the full duration specified in the treatment protocol. If a dose is missed, it must be taken as soon as possible unless the next dose is imminent; do not double the dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Izo

This section provides a summary of the available research on Isosorbide Dinitrate (Izo), focusing on the types of studies conducted and the patterns observed in research findings, without giving clinical advice or overstating certainty.


Evidence for Use in Managing Angina Pectoris (Chest Pain)

Clinical research into the use of Izo for conditions characterized by fluctuating or episodic manifestations of chest pain has primarily involved Randomized Controlled Trials (RCTs) and controlled crossover studies.

Researchers specifically explored whether Izo was associated with a change in the measured duration of exercise before symptoms became more noticeable, and examined outcomes related to the consumption of rescue medication (such as nitroglycerin). These findings contribute to the broader evidence landscape regarding episodic symptom patterns.

Studies exploring short-term symptom changes reported a pattern known as nitrate tolerance, where measured effects on exercise capacity and symptomatic response were observed to diminish or disappear with frequent administration. Research describes that this responsiveness was observed to be restored following a planned nitrate-free interval.


Evidence for Use as Adjunctive Support in Chronic Heart Failure Symptoms

Research examined the compound, primarily in a fixed-dose combination with hydralazine, in conditions marked by functional limitations such as chronic heart failure. These investigations included major long-term survival trials like the V-HeFT and A-HeFT studies, which monitored large cohorts over long observation periods.

Research examined primary outcomes related to outcomes related to all-cause mortality, rates of heart failure-related hospitalizations, and functional capacity. The African-American Heart Failure Trial (A-HeFT) specifically included a cohort of self-identified African-American patients with moderate to severe heart failure and reported that the combination therapy was associated with different outcomes in this population compared to placebo. Research indicates that the evidence for Izo monotherapy and long-term outcomes related to survival remains limited when studied alongside combination therapy and other drug classes.


What Remains Unclear About the Research on Izo

The core evidence for heart failure outcomes applies primarily to the populations studied in the major combination trials, meaning the generalizability of those specific findings to all heart failure cohorts is uncertain. Furthermore, the specific mechanisms underlying the development of nitrate tolerance are complex and remain an active area of research.

Frequently Asked Questions (FAQ)

Common questions about Izo (FAQ)

Q: Are there any common foods or drinks to avoid while taking Izo?

Official product information advises that the consumption of alcohol may increase certain effects of Izo, such as dizziness. Additionally, when taking the sustained-release form of the medication, it has been noted that a high-fat meal may affect the drug's absorption. This recommendation is often associated with official guidelines for maximizing absorption.

Q: How quickly should Izo start working?

The speed at which Izo begins to work depends on the formulation used. The extended-release form is designed for longer-term management and works too slowly to relieve an existing acute attack. However, official information describes that the rapid-acting sublingual route (placed under the tongue) may have an effect that appears within less than 10 minutes of administration.

Q: Does Izo interact with common pain relievers?

Regulatory-backed guidance suggests that some common pain relievers, such as paracetamol (acetaminophen), are described as having no significant interaction risk alongside Izo. However, regulatory documents contain warnings related to the regular use of NSAIDs (non-steroidal anti-inflammatory drugs) like ibuprofen, as these may impact the condition Izo is used to manage.

Q: Is Izo safe for long-term use?

Izo is officially indicated and studied for the long-term prophylaxis (prevention) of angina and is used in the chronic treatment of heart failure. Official documents note that a pattern known as nitrate tolerance may develop with prolonged, frequent use, where the drug's effect lessens over time. The management of tolerance is described as involving a daily drug-free interval as part of the regimen.

Q: Do Izo's effects last all day?

The extended-release form is designed to release the medicine gradually over time, with effects lasting approximately 8 to 10 hours. The need for a drug-free period in the dosing schedule is noted in official guidance as a method for managing nitrate tolerance.

Q: Why do people sometimes feel sleepy after taking Izo?

The official product information lists dizziness and lightheadedness as common side effects stemming from the drug's known action as a potent vasodilator. Regulatory guidance specifically notes that drinking alcohol while taking Izo may increase the risk of these effects, which can also include sleepiness.

Q: Is Izo available in a generic version?

According to the FDA, generic versions of Izo oral tablets are approved and available. However, generic forms of the rapid-acting sublingual tablet and the extended-release capsule/tablet are generally not available in the U.S. market.

Q: Are there any specific supplements that interact with Izo?

Official guidance indicates that regulatory data provide limited information regarding most herbal remedies or supplements used alongside Izo. However, some studies have examined compounds like Vitamin C and N-acetyl Cysteine (NAC) regarding their potential effect on nitrate tolerance.

Q: What kind of research is currently being conducted on Izo?

Official registries like ClinicalTrials.gov list ongoing or recently completed Phase IV studies concerning Izo. This type of research often examines the long-term safety and efficacy of Izo, sometimes in combination with other therapies, within specific patient populations.

Q: What are the most common reasons a doctor might stop prescribing Izo?

The decision to discontinue Izo therapy is based on individualized medical judgment. However, regulatory documents contain warnings about the abrupt discontinuation of the medicine, and dose reduction is noted as often necessary during transition.

Q: Is Izo a controlled substance?

According to official regulatory information, Izo (Isosorbide Dinitrate) is classified as a Human Prescription Drug with no DEA schedule. This classification confirms that the medicine is not considered a controlled substance.

Q: Can Izo affect mood or mental clarity?

Regulatory information notes the need for caution, as Izo is associated with effects that may impact thinking or reactions due to its known vascular actions. These effects include common events like dizziness and potential events like confusion (in cases of overdose).

Q: How long has Izo been approved for use?

The first original brand-name formulation of the active ingredient in Izo, Isosorbide Dinitrate, was approved by the FDA on July 29, 1988. This established its long-term availability for cardiovascular support protocols.

Q: What does official guidance say about driving while using Izo?

Official warnings indicate that if a patient experiences side effects like dizziness, lightheadedness, or low blood pressure, avoiding activities that require high mental alertness is necessary until symptoms resolve. This includes activities such as driving or operating machinery.

Q: If I have mild side effects, is that a sign the Izo is working?

Official drug information describes headaches as a very common side effect of Izo. Regulatory documents note that in some cases, the occurrence of these headaches may be a sign that the medicine is having an effect as intended.

Q: What happens when someone suddenly stops taking Izo?

Official guidance notes that the abrupt discontinuation of Izo is generally associated with an increased risk of adverse side effects. Any change to the prescribed regimen typically involves a gradual dose reduction under the direction of a healthcare professional.

Q: What is the difference between brand-name Izo and a generic form?

Generic tablets contain the identical active ingredient as the brand-name product. However, regulatory documents indicate that the difference lies in the inactive ingredients (such as binders, fillers, or colorants) and the specific manufacturer of the product.

How should Izo be stored and disposed of?

Izo (Isosorbide Dinitrate) must be stored and handled according to specific conditions to maintain its stability and effectiveness, as defined in regulatory labeling.

Storage Conditions

Requirement Official Regulatory Statement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F) [FDA DailyMed].
Protection Keep from freezing, excessive heat, and moisture [NIH MedlinePlus; FDA DailyMed].
Container Keep the medication in the container it came in, with the lid tightly closed [NIH MedlinePlus].
Child Safety Keep out of the reach and sight of children [NIH MedlinePlus].

Disposal Instructions

When discarding unused or expired Izo, regulatory guidelines instruct that the medicine must not be flushed down a toilet or poured into a drain to prevent environmental contamination [NIH MedlinePlus]. Consumers are directed to dispose of the product through an official medicine take-back program or a designated drug disposal site where available [NIH MedlinePlus].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Izo found in:

A-Z Index: